A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment.
SHINE acquires Billerica manufacturing facility and established SPECT product portfolio, expanding leadership in nuclear medicine JANESVILLE, Wis., Jan. 2, 2026 /PRNewswire/ -- SHINE announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results